← Leaderboards
Christopher Eldridge Sims
Altis Biosystems, Inc.
$7,131,837
Attributed
$10,144,099
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,144,099 · 12
By mechanism
R44$8,524,725 · 6
R43$1,619,374 · 6
Top collaborators
- Bill Thelin5 shared
- Elizabeth Boazak2 shared
- Bailey Zwarycz2 shared
Most similar at Altis Biosystems, Inc.
Same institution · by research overlap
- Elizabeth Boazak$546,241
Others in their field
Other Emerging Leaders on “Intestines”
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Gary Fanger · Rise Therapeutics, Llc$20,487,485
- Chun-Jun Guo · Weill Medical Coll Of Cornell Univ$9,142,313
- Jakob H. Von Moltke · University Of Washington$8,392,078
- James W Janetka · Washington University$6,973,678
- Edward Burgard · Dignify Therapeutics, Llc$6,862,973
Research focus
IntestinesCellsPharmacologic SubstanceStem CellsMonolayerReproducibilityPhysiologyGastrointestinalCell TypeIn VitroTissuesPharmaceutical PreparationsIntestinal EpitheliumScreeningScientistBiological ModelsBiotechnologyColonIn VivoBaseHigh Throughput ScreeningIn Vitro ModelOrganoidsPrograms
Grant awards (16)
Mucus and ALI Models of the Human Intestine$835,939
R44 · FY2025 · DK · contact PI
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$913,659
R44 · FY2024 · TR · contact PI
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$988,414
R44 · FY2023 · TR
A 2D Intestinal Crypt Platform for Compound Screens$900,267
R44 · FY2023 · DK · contact PI
MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes.$343,297
R43 · FY2023 · TR · contact PI
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$992,302
R44 · FY2022 · TR
A 2D Intestinal Crypt Platform for Compound Screens$988,431
R44 · FY2022 · DK
A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing$293,991
R43 · FY2022 · DK
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$256,574
R43 · FY2022 · TR
Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system$699,341
R44 · FY2021 · DK · contact PI
A 2D Intestinal Crypt Platform for Compound Screens$256,543
R43 · FY2021 · DK · contact PI
Co-culture cassette for anaerobes and primary human intestinal epithelium$745,742
R44 · FY2020 · DK · contact PI
Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system$712,990
R44 · FY2020 · DK · contact PI
Generating drug-screenable primary human intestinal epithelium by gene-editing and transgenesis$245,920
R43 · FY2020 · DK · contact PI
Co-culture cassette for anaerobes and primary human intestinal epithelium$747,640
R44 · FY2019 · DK · contact PI
Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening$223,049
R43 · FY2019 · DK · contact PI